Nucleic Acid Therapeutics Global Market Report 2025

Description

Nucleic acid therapeutics are a class of treatments that employ nucleic acids-such as deoxyribonucleic acid (DNA), ribonucleic acid (RNA), or their synthetic analogs-to modulate gene expression or correct genetic mutations, addressing diseases at the molecular level. These therapeutics use synthetic DNA or RNA strands to target specific genetic sequences, allowing precise treatment at the molecular and genetic scale.

The primary types of nucleic acid therapeutics include antisense oligonucleotides (ASOs), small interfering RNA (siRNA), gene therapies, aptamers, and others. Antisense oligonucleotides (ASOs) are short synthetic nucleic acid strands designed to bind specific messenger RNA (mRNA) molecules, thereby blocking or altering the expression of target genes. These therapies are applied across multiple therapeutic areas, including neuromuscular, metabolic, cardiovascular, ophthalmological, and oncological disorders. Administration routes include intravenous and subcutaneous methods, and delivery systems encompass viral vector-based and non-viral approaches. Key end users include pharmaceutical companies, biotech firms, and government or academic research institutions.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.

The nucleic acid therapeutics market research report is one of a series of new reports from The Business Research Company that provides nucleic acid therapeutics market statistics, including the nucleic acid therapeutics industry global market size, regional shares, competitors with the nucleic acid therapeutics market share, detailed nucleic acid therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the nucleic acid therapeutics industry. This nucleic acid therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The nucleic acid therapeutics market size has grown rapidly in recent years. It will grow from $6.01 billion in 2024 to $6.94 billion in 2025 at a compound annual growth rate (CAGR) of 15.6%. The growth during the historic period can be attributed to the rising prevalence of genetic and chronic diseases, expanding research and development in genomics, increasing adoption of RNA-based therapeutics, enhanced support from academic and government institutions, and the growing success of mRNA vaccine platforms.

The nucleic acid therapeutics market size is expected to see rapid growth in the next few years. It will grow to $12.24 billion in 2029 at a compound annual growth rate (CAGR) of 15.2%. The growth in the forecast period can be attributed to increasing demand for precision medicine, expansion of mRNA vaccine applications beyond COVID-19, the emergence of next-generation delivery platforms, a growing pipeline of nucleic acid-based therapeutics, and rising regulatory approvals. Key trends during this period include the extension of mRNA platforms into oncology and rare diseases, integration of AI and machine learning in RNA drug discovery, development of targeted delivery systems for tissue-specific effects, modular and multi-target platform therapies, and advancements in next-generation aptamer technologies.

The rising prevalence of genetic and chronic diseases is expected to drive the growth of the nucleic acid therapeutics market in the coming years. Genetic and chronic diseases, such as diabetes, cardiovascular conditions, cancer, and autoimmune disorders, are increasingly being diagnosed due to advancements in diagnostic technologies that allow earlier and more accurate detection. Nucleic acid therapeutics provide targeted and personalized treatment options by regulating, repairing, or silencing specific genes underlying these diseases. For example, according to the Cystic Fibrosis Trust, a UK-based charity, the number of registered cystic fibrosis patients grew from 11,148 in 2022 to 11,318 in 2023, reflecting a 1.5% year-over-year increase, highlighting the growing patient population benefiting from advanced gene-targeted therapies.

Companies in the nucleic acid therapeutics market are developing innovative treatments such as antisense oligonucleotide (ASO) therapies to modulate gene expression in rare and chronic diseases. ASO therapy uses short, synthetic DNA or RNA strands to block or modify the expression of disease-causing genes, offering precision treatment. For instance, in December 2024, Ionis Pharmaceuticals Inc., a US-based biotechnology company, received FDA approval for TRYNGOLZ (olezarsen) as an adjunct therapy to diet for adults with familial chylomicronemia syndrome (FCS), a rare genetic disorder characterized by severe hypertriglyceridemia and elevated risk of acute pancreatitis. TRYNGOLZ represents the first FDA-approved therapy providing significant, sustained triglyceride reduction and a clinically meaningful decrease in acute pancreatitis incidence, administered conveniently via a once-monthly auto-injector.

In June 2025, Novartis AG, a Switzerland-based pharmaceutical company, acquired Regulus Therapeutics Inc., a US-based biotech firm specializing in microRNA-based therapies. This acquisition enhances Novartis's capabilities in RNA-targeted drug development, strengthens its pipeline for rare and chronic disease treatments, and accelerates next-generation nucleic acid therapeutics leveraging Regulus's expertise in microRNA modulation.

Major players in the nucleic acid therapeutics market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Novartis AG, Moderna Inc., BioNTech SE, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Imugene Limited, CureVac SE, Sangamo Therapeutics Inc., Beam Therapeutics Inc., Arbutus Biopharma Corporation, Silence Therapeutics plc, Copernicus Therapeutics Inc., and Exothera S.A.

North America was the largest region in the nucleic acid therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in nucleic acid therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the nucleic acid therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The nucleic acid therapeutics market consists of revenues earned by entities by providing services such as custom oligonucleotide synthesis, gene silencing and editing services, drug discovery and development support, messenger RNA (mRNA) and small interfering RNA (siRNA) design and optimization, and delivery system development. The market value includes the value of related goods sold by the service provider or included within the service offering. The nucleic acid therapeutics market also includes sales of messenger RNA (mRNA) therapeutics, clustered regularly interspaced short palindromic repeats (CRISPR)-based gene editing tools (therapeutic use), aptamers, and Amondys 45 (casimersen). Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Nucleic Acid Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on nucleic acid therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for nucleic acid therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The nucleic acid therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Therapy Type: Antisense Oligonucleotides (ASOs); Small Interfering RNA (siRNA); Gene Therapies; Aptamers; Other Therapy Types
2) By Therapeutic Area: Neuromuscular Disorder; Metabolic Disorders; Cardiovascular Disorders; Ophthalmological Disorders; Oncological Disorders; Other Therapeutic Areas
3) By Route Of Administration: Intravenous; Subcutaneous; Other Route Of Administrations
4) By Delivery Method: Viral Vector-Based Delivery Systems; Non-Viral Delivery Systems
5) By End-Use: Pharmaceutical Companies; Government And Academic Research Institutes; Biotech Companies
Subsegment:
1) By Antisense Oligonucleotides (ASOs): Phosphorothioate ASOs; 2'-O-Methyl ASOs; Locked Nucleic Acid (LNA) ASOs; Gapmer ASOs; Morpholino ASOs
2) By Small Interfering RNA (siRNA): Lipid Nanoparticle (LNP) Formulated siRNA; GalNAc-Conjugated siRNA; Chemically Modified siRNA; Naked siRNA
3) By Gene Therapies: Viral Vector-Based Gene Therapy; Non-Viral Vector-Based Gene Therapy; CRISPR-Based Gene Therapy; Zinc Finger Nucleases (ZFNs); TALENs
4) By Aptamers: Ribonucleic Acid (RNA) Aptamers; Deoxyribonucleic Acid (DNA) Aptamers; Spiegelmers; Pegylated Aptamers
5) By Others Therapy Types: MicroRNA (miRNA) Therapeutics; Long Non-Coding RNA (lncRNA) Therapeutics; Ribonucleic Acid (RNA) Editing Therapies; Ribozymes
Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Sanofi S.A.; Novartis AG; Moderna Inc.; BioNTech SE; Astellas Pharma Inc.; Vertex Pharmaceuticals Incorporated; Alnylam Pharmaceuticals Inc.; Sarepta Therapeutics Inc.; Arrowhead Pharmaceuticals Inc.; Arcturus Therapeutics Holdings Inc.; Imugene Limited; CureVac SE; Sangamo Therapeutics Inc.; Beam Therapeutics Inc.; Arbutus Biopharma Corporation; Silence Therapeutics plc; Copernicus Therapeutics Inc.; Exothera S.A.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r37839

1. Executive Summary

2. Nucleic Acid Therapeutics Market Characteristics

3. Nucleic Acid Therapeutics Market Trends And Strategies

4. Nucleic Acid Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Nucleic Acid Therapeutics Growth Analysis And Strategic Analysis Framework

5.1. Global Nucleic Acid Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Nucleic Acid Therapeutics Market Growth Rate Analysis
5.4. Global Nucleic Acid Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Nucleic Acid Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Nucleic Acid Therapeutics Total Addressable Market (TAM)

6. Nucleic Acid Therapeutics Market Segmentation

6.1. Global Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antisense Oligonucleotides (ASOs)
Small Interfering RNA (siRNA)
Gene Therapies
Aptamers
Other Therapy Types
6.2. Global Nucleic Acid Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Neuromuscular Disorder
Metabolic Disorders
Cardiovascular Disorders
Ophthalmological Disorders
Oncological Disorders
Other Therapeutic Areas
6.3. Global Nucleic Acid Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intravenous
Subcutaneous
Other Route Of Administrations
6.4. Global Nucleic Acid Therapeutics Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Viral Vector-Based Delivery Systems
Non-Viral Delivery Systems
6.5. Global Nucleic Acid Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pharmaceutical Companies
Government And Academic Research Institutes
Biotech Companies
6.6. Global Nucleic Acid Therapeutics Market, Sub-Segmentation Of Antisense Oligonucleotides (ASOs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Phosphorothioate ASOs
2'-O-Methyl ASOs
Locked Nucleic Acid (LNA) ASOs
Gapmer ASOs
Morpholino ASOs
6.7. Global Nucleic Acid Therapeutics Market, Sub-Segmentation Of Small Interfering RNA (siRNA), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Lipid Nanoparticle (LNP) Formulated siRNA
GalNAc-Conjugated siRNA
Chemically Modified siRNA
Naked siRNA
6.8. Global Nucleic Acid Therapeutics Market, Sub-Segmentation Of Gene Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Viral Vector-Based Gene Therapy
Non-Viral Vector-Based Gene Therapy
CRISPR-Based Gene Therapy
Zinc Finger Nucleases (ZFNs)
TALENs
6.9. Global Nucleic Acid Therapeutics Market, Sub-Segmentation Of Aptamers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Ribonucleic Acid (RNA) Aptamers
Deoxyribonucleic Acid (DNA) Aptamers
Spiegelmers
Pegylated Aptamers
6.10. Global Nucleic Acid Therapeutics Market, Sub-Segmentation Of Others Therapy Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
MicroRNA (miRNA) Therapeutics
Long Non-Coding RNA (lncRNA) Therapeutics
Ribonucleic Acid (RNA) Editing Therapies
Ribozymes

7. Nucleic Acid Therapeutics Market Regional And Country Analysis

7.1. Global Nucleic Acid Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Nucleic Acid Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Nucleic Acid Therapeutics Market

8.1. Asia-Pacific Nucleic Acid Therapeutics Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Nucleic Acid Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Nucleic Acid Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Nucleic Acid Therapeutics Market

9.1. China Nucleic Acid Therapeutics Market Overview
9.2. China Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Nucleic Acid Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Nucleic Acid Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Nucleic Acid Therapeutics Market

10.1. India Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Nucleic Acid Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Nucleic Acid Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Nucleic Acid Therapeutics Market

11.1. Japan Nucleic Acid Therapeutics Market Overview
11.2. Japan Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Nucleic Acid Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Nucleic Acid Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Nucleic Acid Therapeutics Market

12.1. Australia Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Nucleic Acid Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Nucleic Acid Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Nucleic Acid Therapeutics Market

13.1. Indonesia Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Nucleic Acid Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Nucleic Acid Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Nucleic Acid Therapeutics Market

14.1. South Korea Nucleic Acid Therapeutics Market Overview
14.2. South Korea Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Nucleic Acid Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Nucleic Acid Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Nucleic Acid Therapeutics Market

15.1. Western Europe Nucleic Acid Therapeutics Market Overview
15.2. Western Europe Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Nucleic Acid Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Nucleic Acid Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Nucleic Acid Therapeutics Market

16.1. UK Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Nucleic Acid Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Nucleic Acid Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Nucleic Acid Therapeutics Market

17.1. Germany Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Nucleic Acid Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Nucleic Acid Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Nucleic Acid Therapeutics Market

18.1. France Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Nucleic Acid Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Nucleic Acid Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Nucleic Acid Therapeutics Market

19.1. Italy Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Nucleic Acid Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Nucleic Acid Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Nucleic Acid Therapeutics Market

20.1. Spain Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Nucleic Acid Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Nucleic Acid Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Nucleic Acid Therapeutics Market

21.1. Eastern Europe Nucleic Acid Therapeutics Market Overview
21.2. Eastern Europe Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Nucleic Acid Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Nucleic Acid Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Nucleic Acid Therapeutics Market

22.1. Russia Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Nucleic Acid Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Nucleic Acid Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Nucleic Acid Therapeutics Market

23.1. North America Nucleic Acid Therapeutics Market Overview
23.2. North America Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Nucleic Acid Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Nucleic Acid Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Nucleic Acid Therapeutics Market

24.1. USA Nucleic Acid Therapeutics Market Overview
24.2. USA Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Nucleic Acid Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Nucleic Acid Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Nucleic Acid Therapeutics Market

25.1. Canada Nucleic Acid Therapeutics Market Overview
25.2. Canada Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Nucleic Acid Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Nucleic Acid Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Nucleic Acid Therapeutics Market

26.1. South America Nucleic Acid Therapeutics Market Overview
26.2. South America Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Nucleic Acid Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Nucleic Acid Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Nucleic Acid Therapeutics Market

27.1. Brazil Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Nucleic Acid Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Nucleic Acid Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Nucleic Acid Therapeutics Market

28.1. Middle East Nucleic Acid Therapeutics Market Overview
28.2. Middle East Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Nucleic Acid Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Nucleic Acid Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Nucleic Acid Therapeutics Market

29.1. Africa Nucleic Acid Therapeutics Market Overview
29.2. Africa Nucleic Acid Therapeutics Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Nucleic Acid Therapeutics Market, Segmentation By Therapeutic Area, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Nucleic Acid Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Nucleic Acid Therapeutics Market Competitive Landscape And Company Profiles

30.1. Nucleic Acid Therapeutics Market Competitive Landscape
30.2. Nucleic Acid Therapeutics Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Moderna Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Nucleic Acid Therapeutics Market Other Major And Innovative Companies

31.1. BioNTech SE
31.2. Astellas Pharma Inc.
31.3. Vertex Pharmaceuticals Incorporated
31.4. Alnylam Pharmaceuticals Inc.
31.5. Sarepta Therapeutics Inc.
31.6. Arrowhead Pharmaceuticals Inc.
31.7. Arcturus Therapeutics Holdings Inc.
31.8. Imugene Limited
31.9. CureVac SE
31.10. Sangamo Therapeutics Inc.
31.11. Beam Therapeutics Inc.
31.12. Arbutus Biopharma Corporation
31.13. Silence Therapeutics plc
31.14. Copernicus Therapeutics Inc.
31.15. Exothera S.A.

32. Global Nucleic Acid Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Nucleic Acid Therapeutics Market

34. Recent Developments In The Nucleic Acid Therapeutics Market

35. Nucleic Acid Therapeutics Market High Potential Countries, Segments and Strategies

35.1 Nucleic Acid Therapeutics Market In 2029 - Countries Offering Most New Opportunities
35.2 Nucleic Acid Therapeutics Market In 2029 - Segments Offering Most New Opportunities
35.3 Nucleic Acid Therapeutics Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer